Osteoarthritis (OA) is a debilitating disease, that imposes a heavy burden on individuals, society, and the healthcare systems. Despite extensive research, the precise pathogenesis of OA remains incompletely defined, hindering the development of targeted therapies. Elucidating OA's molecular mechanisms is fundamental to precision medicine, as it enables identification of diagnostic and prognostic biomarkers while informing tailored treatment strategies. Current clinical guidelines prioritize conservative, non-invasive approaches, however, these demonstrate limited efficacy in halting or reversing disease progression. Within this context, mitochondrial dysfunction has emerged as a critical pathological driver in OA. Specifically, abnormal release of mitochondrial metabolites and components-functioning as damage-associated molecular patterns (mtDAMPs)-triggers inflammatory cascades that accelerate joint degeneration. These mtDAMPs additionally serve as dynamic biomarkers, with their release kinetics correlating with structural deterioration severity. Consequently, mitochondria-targeted therapies restoring mitochondrial quality control represent promising disease-modifying interventions. Here we discuss the origins and roles of key mtDAMPs (mtROS/mtDNA) in OA pathogenesis; their diagnostic and prognostic utility; and therapeutic strategies targeting mitochondrial homeostasis to mitigate OA progression.
21 February 2022 in Annals of the New York Academy of Sciences
Background: We report a case and its 4-year follow-up of Osteoglophonic dysplasia (OD), a rare disease that disturbs both skeletal and dental development, which is usually caused by heterozygous FGFR1 mutations. Case presentation: This article presents a case where a 6-year-old male patient suffered dysregulation of tooth eruption and was diagnosed with osteogenic dysplasia from a fibroblast growth factor receptor 1 (FGFR1) heterozygote mutation. However, the number of teeth is within the normal range, and their roots are well developed. Several interventions were implemented with varying degrees of results. The details of the 4-year follow-up showed that the signs of OD were more pronounced, including dwarfism, frontal bossing, delayed skeletal maturation, anteverted nares, micrognathia, and prominent ears, but the patient’s impacted teeth and edentulous jaws remained unchanged. Conclusions: FGFR1 heterozygote mutation and OD present significant difficulty for teeth eruption and subsequent intervention. Further measures ought to be taken in recognizing various symptoms presented by the patient. This case supports the significance of careful inquiry, comprehensive physical examination and correct diagnosis as indispensable steps for clinical practice in patients with unerupted teeth. Additionally, the detailed case and its 4-year follow-up length may provide new insights into osteogenic dysplasia and patients with impacted teeth while encouraging further exploration in treatment methods.